Inhibition of the Wnt-β-catenin and Notch signaling pathways sensitizes osteosarcoma cells to chemotherapy

Biochemical and Biophysical Research Communications

Volumn 431, Issue 2, 2013, Pages 274-279

  Ma, Yimin ^a   Ren, Yongxin ^a   Han, Ethan Q ^b   Li, Huiwu ^c   Chen, Di ^d   Jacobs, Joshua J ^d   Gitelis, Steven ^d   O'Keefe, Regis J ^e   Konttinen, Yrjö T ^f   Yin, Guoyong ^a   Li, Tian Fang ^d,g  

^a NANJING MEDICAL UNIVERSITY   (China)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^f UNIVERSITY OF HELSINKI   (Finland)

^g Department of Biochemistry ^*  (United States)

Author keywords

Apoptosis; Catenin; Methotrexate; Notch; Osteosarcoma; Pathway

Indexed keywords

BETA CATENIN; LYMPHOID ENHANCER FACTOR 1; METHOTREXATE; NOTCH RECEPTOR; WNT3A PROTEIN;

ARTICLE; CELL DEATH; CHEMOSENSITIVITY; CHEMOSENSITIZATION; CONTROLLED STUDY; FETUS; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; OSTEOBLAST; OSTEOSARCOMA CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; UPREGULATION;

BETA CATENIN; BONE NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HEDGEHOG PROTEINS; HUMANS; OSTEOSARCOMA; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; WNT PROTEINS;

ERINACEIDAE;

EID: 84873430058     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.12.118     Document Type: Article

References (30)

1. Messerschmitt P.J., Garcia R.M., Abdul-Karim F.W., Greenfield E.M., Getty P.J. Osteosarcoma. J. Am. Acad. Orthop. Surg. 2009, 17:515-527.
2. Ritter J., Bielack S.S. Osteosarcoma. Ann. Oncol. 2010, 21S:320-325.
3. Geller D.S., Gorlick R. Osteosarcoma. Cin. Adv. Hematol. Oncol. 2010, 8:705-718.
4. Federman N., Bernthal N., Eilber F.C., Tap W.D. The multidisciplinary management of osteosarcoma. Options Oncol. Curr. Treat. 2009, 10:82-93.
5. Niswander L.M., Kim S.Y. Stratifying osteosarcoma: minimizing and maximizing therapy. Curr. Oncol. Rep. 2010, 12:266-270.
6. D'Adamo D.R. Appraising the current role of chemotherapy for the treatment of sarcoma. Semin. Oncol. 2011, 38S:19-29.
7. Grimer R.J. Surgical options for children with osteosarcoma. Lancet Oncol. 2005, 6:85-92.
8. Ferrari S., Palmerini E. Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr. Opin. Oncol. 2007, 19:341-346.
9. Chou A.J., Geller D.S., Gorlick R. Therapy for osteosarcoma. Paediatr. Drugs 2008, 10:315-327.
10. Jeon D.G., Song W.S. How can survival be improved in localized osteosarcoma?. Expert Rev. Anticancer Ther. 2010, 10:1313-1325.
11. Janeway K.A., Grier H.E. Sequelae of osteosarcoma medical therapy. Lancet Oncol. 2010, 11:670-678.
12. Walters D.K., Steinmann P., Langsam B., Schmutz S., Born W., Fuchs B. Identification of potential chemoresistance genes in osteosarcoma. Anticancer Res. 2008, 28:673-679.
13. Kansara M., Tsang M., Kodjabachian L., Sims N.A., Trivett M.K., Ehrich M., Dobrovic A., Slavin J., Choong P.F., Simmons P.J., Dawid I.B., Thomas D.M. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J. Clin. Invest. 2009, 119:837-851.
14. McQueen P., Ghaffar S., Guo Y., Rubin E.M., Zi X., Hoang B.H. The Wnt signaling pathway: implications for therapy in osteosarcoma. Expert Rev. Anticancer Ther. 2011, 11:1223-1232.
15. Nagao H., Ijiri K., Hirotsu M., Ishidou Y., Yamamoto T., Nagano S., Takizawa T., Nakashima K., Komiya S., Setoguchi T. Role of GLI2 in the growth of human osteosarcoma. J. Pathol. 2011, 224:169-179.
16. Tao J., Chen S., Lee B. Alteration of Notch signaling in skeletal development and disease. Ann. NY. Acad. Sci. 2010, 1192:257-268.
17. Hoang B.H., Kubo T., Healey J.H., Sowers R., Mazza B., Yang R., Huvos A.G., Meyers P.A., Gorlick R. Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int. J. Cancer 2004, 109:106-111.
18. Iwaya K., Ogawa H., Kuroda M., Izumi M., Ishida T., Mukai K. Cytoplasmic and/or nuclear staining of beta-catenin is associated with lung metastasis. Clin. Exp. Metastasis 2003, 20:525-529.
19. Rubin E.M., Guo Y., Tu K., Xie J., Zi X., Hoang B.H. Wnt inhibitory factor 1 decreases tumorigenesis and metastasis in osteosarcoma. Mol. Cancer Ther. 2010, 9:731-741.
20. Hoang B.H., Kubo T., Healey J.H., Yang R., Nathan S.S., Kolb E.A., Mazza B., Meyers P.A., Gorlick R. Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer Res. 2004, 64:2734-2739.
21. Cai Y., Mohseny A.B., Karperien M., Hogendoorn P.C., Zhou G., Cleton-Jansen A.M. Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma. J. Pathol. 2010, 220:24-33.
22. Zhang P., Yang Y., Zweidler-McKay P.A., Hughes D.P. Critical role of notch signaling in osteosarcoma invasion and metastasis. Clin. Cancer Res. 2008, 14:2962-2969.
23. Engin F., Bertin T., Ma O., Jiang M.M., Wang L., Sutton R.E., Donehower L.A., Lee B. Notch signaling contributes to the pathogenesis of human osteosarcomas. Hum. Mol. Genet. 2009, 18:1464-1470.
24. Tanaka M., Setoguchi T., Hirotsu M., Gao H., Sasaki H., Matsunoshita Y., Komiya S. Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation. Br. J. Cancer 2009, 100:1957-1965.
25. Zhang P., Yang Y., Nolo R., Zweidler-McKay P.A., Hughes D.P. Regulation of NOTCH signaling by reciprocal inhibition of HES1 and Deltex 1 and its role in osteosarcoma invasiveness. Oncogene 2010, 29:2916-2926.
26. Warzecha J., Göttig S., Chow K.U., Brüning C., Percic D., Boehrer S., Brude E., Kurth A. Inhibition of osteosarcoma cell proliferation by the Hedgehog-inhibitor cyclopamine. J. Chemother. 2007, 19:554-561.
27. Warzecha J., Dinges D., Kaszap B., Henrich D., Marzi I., Seebach C. Effect of the Hedgehog-inhibitor cyclopamine on mice with osteosarcoma pulmonary metastases. Int. J. Mol. Med. 2012, 29:423-427.
28. Lin P.P., Pandey M.K., Jin F., Raymond A.K., Akiyama H., Lozano G. Targeted mutation of p53 and Rb in mesenchymal cells of the limb bud produces sarcomas in mice. Carcinogenesis 2009, 30:1789-1795.
29. Walkley C.R., Qudsi R., Sankaran V.G., Perry J.A., Gostissa M., Roth S.I., Rodda S.J., Snay E., Dunning P., Fahey F.H., Alt F.W., McMahon A.P., Orkin S.H. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev. 2008, 22:1662-1676.
30. Adhikari A.S., Agarwal N., Wood B.M., Porretta C., Ruiz B., Pochampally R.R., Iwakuma T. CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res. 2010, 70:4602-4612.